Advanced in Leukemia

Jerome L. Rey

Marseille, FR 
Advanced in Leukemia
Marseille, FR 
OverviewLocationsClinical Research

Overview

Jerome Rey practices in Marseille, France. Mr. Rey is rated as an Advanced expert by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelofibrosis, Myeloproliferative Neoplasms (MPN), and Lymphomatoid Papulosis.

His clinical research consists of co-authoring 70 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 34 articles and participated in 2 clinical trials in the study of Leukemia.

Gender
Male

Locations

Marseille, France
Other Locations
Metz, 57000, France
14000, France
Nancy, France
Lyon, 69364, France
Rond Point De L'échangeur De Solaize, BP3, Solaize, 69360, France
Villeneuve-sur-lot, France
Bagnols-en-foret, 30207, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia
Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drugs: Methotrexate, Cyclophosphamide
Study Phase: Phase 2
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Enrollment Status: Completed
Publish Date: August 18, 2022
Intervention Type: Drug
Study Drug: Nilotinib
Study Phase: Phase 2
View 1 Less Clinical Trial

70 Total Publications

Gene expression-based rationale for investigating CDK4/6 inhibitors in primitive myelofibrosis.
Gene expression-based rationale for investigating CDK4/6 inhibitors in primitive myelofibrosis.
Journal: Leukemia
Published: March 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rey's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile